Soluble Receptor for Advanced Glycation End Products (sRAGE) is Up-Regulated in Multiple Sclerosis Patients Treated with Interferon β-1a | Zendy

Mehrali Rahimi | Zendy; Sarah Saadat Aghabozorg Afjeh | Zendy; Mir Davood Omrani | Zendy; Shahram ArsangJang | Zendy; Maziar Ganji | Zendy; Rezvan Noroozi | Zendy; Mohammad Taheri | Zendy; Soudeh GhafouriFard | Zendy

Open Access

Soluble Receptor for Advanced Glycation End Products (sRAGE) is Up-Regulated in Multiple Sclerosis Patients Treated with Interferon β-1a

Author(s) -

Mehrali Rahimi,

Sarah Saadat Aghabozorg Afjeh,

Mir Davood Omrani,

Shahram ArsangJang,

Maziar Ganji,

Rezvan Noroozi,

Mohammad Taheri,

Soudeh GhafouriFard

Publication year - 2018

Publication title -

cellular physiology and biochemistry

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.486

H-Index - 87

eISSN - 1421-9778

pISSN - 1015-8987

DOI - 10.1159/000488622

Subject(s) - multiple sclerosis , rage (emotion) , glycation , pathogenesis , medicine , receptor , immune system , immunology , expanded disability status scale , inflammation , endocrinology , biology , neuroscience

Multiple sclerosis (MS) is a chronic inflammatory disorder of the central nervous system. Considering the role of immune system in its pathogenesis, researchers have focused on evaluation of the expression of immune-related genes or proteins in MS patients. Among proteins whose participation in inflammatory process has been documented is the receptor for advanced glycation end products (RAGE).

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research